Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Commerce Bank

Commerce Bank raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 72,494 shares of the biopharmaceutical company’s stock after buying an additional 7,055 shares during the quarter. Commerce Bank’s holdings in Gilead Sciences were worth $6,078,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Prospera Private Wealth LLC increased its stake in Gilead Sciences by 18.9% in the third quarter. Prospera Private Wealth LLC now owns 15,144 shares of the biopharmaceutical company’s stock valued at $1,270,000 after purchasing an additional 2,407 shares during the last quarter. Avior Wealth Management LLC raised its position in Gilead Sciences by 1.2% in the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 108 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Gilead Sciences by 7.5% during the third quarter. PNC Financial Services Group Inc. now owns 390,175 shares of the biopharmaceutical company’s stock valued at $32,712,000 after purchasing an additional 27,283 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Gilead Sciences during the third quarter worth about $9,516,000. Finally, Fifth Third Wealth Advisors LLC grew its holdings in Gilead Sciences by 11.9% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 12,862 shares of the biopharmaceutical company’s stock worth $1,078,000 after acquiring an additional 1,364 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on GILD shares. Robert W. Baird increased their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Piper Sandler upped their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Citigroup initiated coverage on Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 target price for the company. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Finally, Sanford C. Bernstein initiated coverage on Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective on the stock. Twelve analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $95.41.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 1.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 27.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,947 shares of company stock valued at $4,968,674 in the last 90 days. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $89.84 on Friday. The business’s 50-day simple moving average is $87.28 and its 200-day simple moving average is $76.61. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The firm has a market cap of $111.96 billion, a price-to-earnings ratio of 998.22, a P/E/G ratio of 2.72 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.29 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 4.38 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.43%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.